BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: A meta-analysis. World J Hepatol 2015; 7(5): 806-813 [PMID: 25914781 DOI: 10.4254/wjh.v7.i5.806]
URL: https://www.wjgnet.com/1948-5182/full/v7/i5/806.htm
Number Citing Articles
1
Shih Yea Sylvia Wu, Bridget Faire, Edward Gane. Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse ReactionCase Reports in Medicine 2017; 2017: 1 doi: 10.1155/2017/4895736
2
Danyu Ye, Zhengyi Bao, Yang Yu, Zhenbo Han, Ying Yu, Zihang Xu, Wenya Ma, Ye Yuan, Lai Zhang, Yan Xu, Tianshuai Ma, Shenzhen Liu, Xinlu Gao, Gege Yan, Qi Huang, Xiuxiu Wang, Bingjie Hua, Fan Yang, Yuan Li, Benzhi Cai. Inhibition of cardiomyocyte differentiation of human induced pluripotent stem cells by Ribavirin: Implication for its cardiac developmental toxicityToxicology 2020; 435: 152422 doi: 10.1016/j.tox.2020.152422
3
Karin Hepp Schwambach, Mareni Rocha Farias, Giácomo Balbinotto Neto, Carine Raquel Blatt. Cost and Effectiveness of the Treatment of Chronic Hepatitis C in Brazil: Real-World DataValue in Health Regional Issues 2020; 23: 49 doi: 10.1016/j.vhri.2020.05.002
4
Saikiran M Kilaru, Ira M Jacobson. Sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infectionFuture Virology 2019; 14(2): 61 doi: 10.2217/fvl-2018-0134
5
Jorge Mera, Claudia Vellozzi, Susan Hariri, Hélène Carabin, Douglas A. Drevets, Anna Miller, Brigg Reilley, Whitney Essex, David Gahn, Lisa Lyons, Jessica Leston, John W. Ward. Identification and Clinical Management of Persons with Chronic Hepatitis C Virus Infection — Cherokee Nation, 2012–2015MMWR. Morbidity and Mortality Weekly Report 2016; 65(18): 461 doi: 10.15585/mmwr.mm6518a2
6
Andrew H Talal, Emily O Dumas, Barbara Bauer, Richard M Rejman, Andrew Ocque, Gene D Morse, Danijela Lucic, Gavin A Cloherty, Jennifer King, Jiuhong Zha, Hongtao Zhang, Daniel E Cohen, Nancy Shulman, Jean-Michel Pawlotsky, Christophe Hézode. Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin DosageThe Journal of Infectious Diseases 2018; 217(3): 474 doi: 10.1093/infdis/jix495
7
Grace Y. Zhang, Krupa Patel, Olufunso Agbalajobi, Wheytnie Alexandre, Andrea Reid, Marina Serper, Linda Calgaro, Susan Zickmund, Tami Coppler, Margaret Mizah, Obaid Shaikh, Shari Rogal. Patient perceptions of successful hepatitis C virus treatment adherence in VeteransGastroHep 2021; 3(5): 307 doi: 10.1002/ygh2.474
8
Thanthima Suwanthawornkul, Thunyarat Anothaisintawee, Abhasnee Sobhonslidsuk, Ammarin Thakkinstian, Yot Teerawattananon, Ravi Jhaveri. Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-AnalysisPLOS ONE 2015; 10(12): e0145953 doi: 10.1371/journal.pone.0145953
9
Myron John Tong, Patrick Weijen Chang, Thatcher Thi Huynh, Alexander Anthony Rosinski, Lori Terese Tong. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experienceJournal of Digestive Diseases 2016; 17(2): 113 doi: 10.1111/1751-2980.12313
10
Mustafa S Ascha, Mona L Ascha, Ibrahim A Hanouneh. Management of immunosuppressant agents following liver transplantation: Less is moreWorld Journal of Hepatology 2016; 8(3): 148-161 doi: 10.4254/wjh.v8.i3.148
11
Ke Zheng, Si-zhi Wu, Yi-wen Lv, Peng Pang, Li Deng, Hua-chong Xu, Yu-cong Shi, Xiao-yin Chen. Carvacrol inhibits the excessive immune response induced by influenza virus A via suppressing viral replication and TLR/RLR pattern recognitionJournal of Ethnopharmacology 2021; 268: 113555 doi: 10.1016/j.jep.2020.113555
12
John Davison, Amy O’Shea, Nancee Waterbury, Yolanda Villalvazo. Examining Hepatitis, A and B Vaccination, and HBV Reactivation Monitoring During Direct-Acting Antiviral Therapy for Hepatitis CJournal of Community Health 2018; 43(6): 1124 doi: 10.1007/s10900-018-0530-0
13
Rodolfo Castro, Hugo Perazzo, Beatriz Grinsztejn, Valdilea G. Veloso, Chris Hyde. Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian PerspectiveInternational Journal of Hepatology 2015; 2015: 1 doi: 10.1155/2015/852968
14
Rowan Ahmed, Roaa Kareem, Nanditha Venkatesan, Rinky A Botleroo, Opemipo D Ogeyingbo, Renu Bhandari, Mallika Gyawali, Abeer O Elshaikh. Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus InfectionCureus 2021;  doi: 10.7759/cureus.17237
15
Juan F. Yepes. The ADA Practical Guide to Patients with Medical Conditions2015; : 121 doi: 10.1002/9781119121039.ch6
16
Angus W Jeffrey, Yi Huang, W Bastiaan de Boer, Leon A Adams, Gerry MacQuillan, David Speers, John Joseph, Gary P Jeffrey. Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcomeWorld Journal of Hepatology 2017; 9(19): 850-856 doi: 10.4254/wjh.v9.i19.850
17
Jean-Baptiste Trabut, Camille Barrault, Hélène Charlot, Damien Carmona, Anne Bourdel, Mustapha Benslimane, Murielle François, Willy Kini-Matondo, Richard Causse, Françoise Roudot-Thoraval, Christophe Hézode. Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use DisorderJournal of Addiction Medicine 2018; 12(5): 346 doi: 10.1097/ADM.0000000000000415
18
Rachel Webster, Miranda S. Moore, Angelica Bocour, Nirah Johnson, Ann Winters. Health Department Efforts to Increase Hepatitis C RNA Testing Among People Appearing Out of Care: Comparison of Outreach Approaches, New York City, 2017Public Health Reports 2020; 135(6): 823 doi: 10.1177/0033354920952068
19
Miranda S. Moore, Angelica Bocour, Fabienne Laraque, Ann Winters. A Surveillance-Based Hepatitis C Care Cascade, New York City, 2017Public Health Reports 2018; 133(4): 497 doi: 10.1177/0033354918776641
20
Thidarath Rattanaburee, Mutita Junking, Aussara Panya, Nunghathai Sawasdee, Pucharee Songprakhon, Aroonroong Suttitheptumrong, Thawornchai Limjindaporn, Guy Haegeman, Pa-thai Yenchitsomanus. Inhibition of dengue virus production and cytokine/chemokine expression by ribavirin and compound AAntiviral Research 2015; 124: 83 doi: 10.1016/j.antiviral.2015.10.005
21
Coralie Hermetet, Frederic Dubois, Catherine Gaudy-Graffin, Yannick Bacq, Bernard Royer, Christophe Gaborit, Louis D’Alteroche, Jean Claude Desenclos, Philippe Roingeard, Leslie Grammatico-Guillon, Yury E. Khudyakov. Continuum of hepatitis C care in France: A 20-year cohort studyPLOS ONE 2017; 12(8): e0183232 doi: 10.1371/journal.pone.0183232
22
Ekta Gupta, Pragya Agarwala, Guresh Kumar, Rakhi Maiwall, Shiv Kumar Sarin. Point -of -care testing (POCT) in molecular diagnostics: Performance evaluation of GeneXpert HCV RNA test in diagnosing and monitoring of HCV infectionJournal of Clinical Virology 2017; 88: 46 doi: 10.1016/j.jcv.2017.01.006
23
Bassem Refaat, Adel Galal El-Shemi, Ahmed Mohamed Ashshi, Elaf Wael Mahamid, Noha Mohammed Al-Qadi. Pegylated Interferon-αModulates Liver Concentrations of Activin-A and Its Related Proteins in Normal Wistar RatMediators of Inflammation 2015; 2015: 1 doi: 10.1155/2015/414207
24
Ryo Iketani, Kazuki Ide, Hiroshi Yamada, Yohei Kawasaki, Naohiko Masaki. The Safety Profile of Telaprevir-Based Triple Therapy in Clinical Practice: A Retrospective Cohort StudyBiological & Pharmaceutical Bulletin 2017; 40(5): 687 doi: 10.1248/bpb.b16-00989
25
Shivank Madan, Snehal R. Patel, Kusha Rahgozar, Omar Saeed, Sandhya Murthy, Sasa Vukelic, Daniel B. Sims, Jooyoung Julia Shin, Daniel J. Goldstein, Ulrich P. Jorde. Utilization rates and clinical outcomes of hepatitis C positive donor hearts in the contemporary eraThe Journal of Heart and Lung Transplantation 2019; 38(9): 907 doi: 10.1016/j.healun.2019.06.023
26
Lingyao Du, Hong Tang. miRNA antagonism and direct-acting antivirals: could this be a novel combination treatment against HCV?Future Virology 2016; 11(12): 753 doi: 10.2217/fvl-2016-0109
27
Naganori Kamiyama, Ryusuke Soma, Shinya Hidano, Kei Watanabe, Hiroshi Umekita, Chiaki Fukuda, Kaori Noguchi, Yoshiko Gendo, Takashi Ozaki, Akira Sonoda, Nozomi Sachi, Lucky Ronald Runtuwene, Yumako Miura, Etsuro Matsubara, Shigeru Tajima, Tomohiko Takasaki, Yuki Eshita, Takashi Kobayashi. Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient miceAntiviral Research 2017; 146: 1 doi: 10.1016/j.antiviral.2017.08.007
28
L. Benítez-Gutiérrez, C. de Mendoza, I. Baños, A. Duca, A. Arias, A. Treviño, S. Requena, M.J. Citores, V. Cuervas-Mons. Drug-Induced Lung Injury in a Liver Transplant Patient Treated With SofosbuvirTransplantation Proceedings 2016; 48(7): 2515 doi: 10.1016/j.transproceed.2016.08.026
29
Xiaobo Zhu, Mingqi Wang, Mei Liu, Xinghao Yu, Peng Huang. Efficacy and safety of direct-acting antivirals for treatment-naive patients with genotype 1 hepatitis C virus infectionPersonalized Medicine 2019; 16(5): 421 doi: 10.2217/pme-2018-0121
30
Arshia Alimohammadi, Julie Holeksa, Astou Thiam, David Truong, Brian Conway. Real-world Efficacy of Direct-Acting Antiviral Therapy for HCV Infection Affecting People Who Inject Drugs Delivered in a Multidisciplinary SettingOpen Forum Infectious Diseases 2018; 5(6) doi: 10.1093/ofid/ofy120
31
Helen Caldwell. Preventing, identifying and treating hepatitis CNursing Standard 2019; 34(1): 68 doi: 10.7748/ns.2018.e11321
32
John C. Christenson, John J. Manaloor. Hepatitis A, B, and CPediatrics in Review 2016; 37(10): 426 doi: 10.1542/pir.2015-0075
33
P Abraham. Treatment for hepatitis C virus infection in India: Promising timesIndian Journal of Medical Microbiology 2016; 34(3): 273 doi: 10.4103/0255-0857.188312
34
Krupa Patel, Susan L. Zickmund, Harleigh Jones, Andrea Reid, Linda Calgaro, Arielle Otero, Tami Coppler, Shari S. Rogal. Determinants of Hepatitis C Treatment Adherence and Treatment Completion Among Veterans in the Direct Acting Antiviral EraDigestive Diseases and Sciences 2019; 64(10): 3001 doi: 10.1007/s10620-019-05590-x
35
Alejandro Pérez-Pitarch, Beatriz Guglieri-López, Rafael Ferriols-Lisart, Matilde Merino-Sanjuán. A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patientsInternational Journal of Antimicrobial Agents 2016; 47(3): 184 doi: 10.1016/j.ijantimicag.2015.12.008
36
H. Wedemeyer, A. Craxí, E. Zuckerman, D. Dieterich, R. Flisiak, S. K. Roberts, A. Pangerl, Z. Zhang, M. Martinez, Y. Bao, J.-L. Calleja. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysisJournal of Viral Hepatitis 2017; 24(11): 936 doi: 10.1111/jvh.12722
37
Salamat Ali, Tofeeq Ur-Rehman, Mashhood Ali, Sayeed Haque, Faisal Rasheed, Eleri Lougher, Muhammad Sarfraz Nawaz, Vibhu Paudyal. Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programmeInternational Journal of Clinical Pharmacy 2021; 43(4): 958 doi: 10.1007/s11096-020-01202-1
38
Miranda S. Moore, Angelica Bocour, Lizeyka Jordan, Emily McGibbon, Jay K. Varma, Ann Winters, Fabienne Laraque. Development and Validation of Surveillance-Based Algorithms to Estimate Hepatitis C Treatment and Cure in New York CityJournal of Public Health Management and Practice 2018; 24(6): 526 doi: 10.1097/PHH.0000000000000688
39
Peng Huang, Yan Wang, Ming Yue, Zhijun Ge, Xueshan Xia, Andre J. Jeyarajan, Jacinta A. Holmes, Rongbin Yu, Chuanwu Zhu, Sheng Yang, Wenyu Lin, Raymond T. Chung. The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysisLiver International 2021; 41(10): 2341 doi: 10.1111/liv.14976
40
Tu M. Pham, Si C. Tran, Yun-Sook Lim, Soon B. Hwang, J.-H. James Ou. Hepatitis C Virus-Induced Rab32 Aggregation and Its Implications for Virion AssemblyJournal of Virology 2017; 91(3) doi: 10.1128/JVI.01662-16